share_log

HOOKIPA Pharma | 8-K: HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

HOOKIPA Pharma | 8-K: HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

HOOKIPA Pharma | 8-K：HOOKIPA Pharma公布2024年第一季度财务业绩和近期业务亮点
美股sec公告 ·  05/09 07:07
Moomoo AI 已提取核心信息
On May 9, 2024, HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, announced its financial results for the first quarter of 2024. The company, listed on the Nasdaq Capital Market under the symbol HOOK, reported significant progress in its clinical programs, including the preparation for a pivotal Phase 2/3 trial of HB-200 in combination with pembrolizumab for the treatment of HPV16+ recurrent or metastatic OPSCC. The trial design aligns with FDA feedback and is expected to begin in the fourth quarter of 2024. HOOKIPA also received PRIME designation from the EMA for HB-200 and FDA clearance for an IND application for HB-700 for KRAS mutated cancers. The company's infectious disease programs, HB-400 and HB-500, are advancing in collaboration with Gilead Sciences, with HB-500 expected to...Show More
On May 9, 2024, HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, announced its financial results for the first quarter of 2024. The company, listed on the Nasdaq Capital Market under the symbol HOOK, reported significant progress in its clinical programs, including the preparation for a pivotal Phase 2/3 trial of HB-200 in combination with pembrolizumab for the treatment of HPV16+ recurrent or metastatic OPSCC. The trial design aligns with FDA feedback and is expected to begin in the fourth quarter of 2024. HOOKIPA also received PRIME designation from the EMA for HB-200 and FDA clearance for an IND application for HB-700 for KRAS mutated cancers. The company's infectious disease programs, HB-400 and HB-500, are advancing in collaboration with Gilead Sciences, with HB-500 expected to enter Phase 1 trials in Q2 2024. Financially, HOOKIPA received a $10 million milestone payment from Roche and reported total revenues of $36.6 million, leading to a profitable quarter with a net income of $14.4 million. This contrasts with a net loss of $19.7 million in the same period of the previous year. The company's cash position as of March 31, 2024, was $93.0 million.
2024年5月9日，临床阶段的生物制药公司HOOKIPA Pharma Inc. 公布了其2024年第一季度的财务业绩。该公司在纳斯达克资本市场上市，股票代码为HOOK，该公司报告了其临床项目取得的重大进展，包括为 HB-200 与pembrolizumab联合治疗HPV16+复发性或转移性OPSCC的关键性2/3期试验做准备。该试验设计符合美国食品药品管理局的反馈，预计将于2024年第四季度开始。HOOKIPA 还获得了 EMA 颁发的 HB-200 PRIME 称号，并批准了 KRAS 突变癌症的 HB-700 的 IND 申请。该公司的传染病项目 HB-400 和 HB-500 正在与吉...展开全部
2024年5月9日，临床阶段的生物制药公司HOOKIPA Pharma Inc. 公布了其2024年第一季度的财务业绩。该公司在纳斯达克资本市场上市，股票代码为HOOK，该公司报告了其临床项目取得的重大进展，包括为 HB-200 与pembrolizumab联合治疗HPV16+复发性或转移性OPSCC的关键性2/3期试验做准备。该试验设计符合美国食品药品管理局的反馈，预计将于2024年第四季度开始。HOOKIPA 还获得了 EMA 颁发的 HB-200 PRIME 称号，并批准了 KRAS 突变癌症的 HB-700 的 IND 申请。该公司的传染病项目 HB-400 和 HB-500 正在与吉利德科学合作推进，HB-500 预计将在2024年第二季度进入第一阶段试验。财务方面，HOOKIPA从罗氏获得了1000万美元的里程碑式付款，报告的总收入为3660万美元，本季度实现了盈利，净收入为1,440万美元。与此形成鲜明对比的是，去年同期的净亏损为1,970万美元。截至2024年3月31日，该公司的现金状况为9,300万美元。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息